PAM
AZN icon

Palisade Asset Management’s AstraZeneca AZN Stock Holding History

Palisade Asset Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-796
Closed -$122K – 234
2025
Q3 		$122K Buy
+796
New +$120K 0.01% 223
2024
Q2 		– Sell
-280
Closed -$37.9K – 211
2024
Q1 		$37.9K Buy
+280
New +$37.1K ﹤0.01% 284

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Palisade Asset Management's AZN Position: Q4 2025 in Review

Palisade Asset Management sold out of AstraZeneca (AZN) in Q4 2025, closing a stake of 796 shares — an estimated $122K sold.

Palisade Asset Management first reported a position in AZN in Q1 2024 and held it in 2 quarters. The position peaked at $122K in Q3 2025. 1,408 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

  • Palisade Asset Management reported no remaining AstraZeneca position as of Q4 2025 after selling out during the quarter.
  • Palisade Asset Management sold 796 AstraZeneca shares in Q4 2025, an estimated $122K.
  • Palisade Asset Management first reported a position in AstraZeneca in Q1 2024 and held it in 2 quarters.
  • Palisade Asset Management's AstraZeneca position peaked at $122K in Q3 2025.
  • 1,408 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on Palisade Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.